A key advantage of both Pfizer and Merck’s active ingredients is that they can be taken as a simple tablet.
(Photo: Reuters)
Frankfurt The US pharmaceutical company Pfizer is raising hopes for a simple and highly effective therapy against Covid-19. According to new study data, the drug Paxlovid, which can be taken as a tablet, reduces the risk of severe disease and death in patients at increased risk by 89 percent, Pfizer announced on Friday morning.
The US group now wants to incorporate the data into an ongoing, rolling approval process at the US FDA as soon as possible. An emergency approval in the USA seems conceivable this year. Pfizer is also likely to seek rapid approval in Europe.
Overall, the results for the Pfizer drug were significantly better than the data for the active ingredient molnupiravir, for which the competitor Merck & Co. had reported a risk reduction of around 50 percent a few weeks ago. Even then, some experts spoke of a turning point in Covid therapy.
Read on now
Get access to this and every other article in the
Web and in our app for 4 weeks free of charge.
Further
Read on now
Get access to this and every other article in the
Web and in our app for 4 weeks free of charge.
Further